The full results of SHIMMER, the first controlled trial of the sigma-2 receptor modulator zervimesine (CT1812) in dementia with Lewy bodies, were published in Alzheimer's & Dementia on December 19, 2025 by James E. Galvin of the University of Miami Miller School of Medicine and colleagues, including employees of the sponsor, Cognition Therapeutics. The trial (COG1201, NCT05225415) screened 293 people aged 50 to 85 with probable DLB and Mini-Mental State Examination scores of 18 to 27, randomly assigned 130 of them to once-daily oral zervimesine 100 mg, zervimesine 300 mg or placebo for 26 weeks, and saw 109 (83.8 percent) complete. Its primary endpoint was safety and tolerability, which it met. All efficacy measures were exploratory, a point the paper states plainly.

The number the company has quoted most, an 86 percent slowing of decline on the 12-item Neuropsychiatric Inventory, is a percentage derived from a difference of 5.0 points between pooled zervimesine (n = 88) and placebo (n = 42) at week 26. The paper reports that difference with a 95 percent confidence interval of -10.1 to 0.1 and p = 0.055, meaning the range of results compatible with the data still includes no benefit at all. The linked measure of care partner distress on the NPI-12 was -3.1 (95 percent CI -5.9 to -0.4, p = 0.025). Other exploratory measures moved in the same direction without reaching significance: cognitive fluctuations on the Clinician Assessment of Fluctuation, -1.0 (95 percent CI -2.6 to 0.6), and motor scores on MDS-UPDRS Part III, -2.9 (95 percent CI -7.3 to 1.5, p = 0.191).

On safety, discontinuation for treatment-related adverse events was 4.5 percent at 100 mg, 16.3 percent at 300 mg and 4.8 percent on placebo. Three deaths (2.3 percent) occurred, all reported as unrelated to treatment. The most common treatment-emergent events across the trial were falls (24.0 percent), headache (14.7 percent), raised lipase (14.0 percent) and urinary tract infection (10.9 percent). Liver enzyme elevations were dose related and reversed on stopping the drug, with no signal of serious liver injury; the authors conclude that future studies should focus on the lower dose, since efficacy looked similar at both. The trial was supported by a National Institute on Aging grant of about 30 million dollars (R01AG071643) and run in collaboration with the Lewy Body Dementia Association.

The behavioural signal, rather than global progression, is now the programme. On June 24, 2026 Cognition said written feedback from the US Food and Drug Administration agreed that DLB psychosis could be an approvable outcome, and that key elements of a registrational trial were acceptable: people with DLB who have hallucinations and delusions, including those on stable off-label antipsychotics, randomly assigned to 100 mg zervimesine or placebo for nine months, with the NPI proposed as a novel primary endpoint. The company cited a later analysis putting the slowing of hallucinations and delusions at 89 percent, described by trade coverage as post hoc. That programme is expected to begin in mid-2027, and no drug is approved for DLB or for its psychosis.